Ciro Ahumada, new Global CEO of Qualicaps
Qualicaps®, part of Mitsubishi Chemical Holding Corporation, has named Ciro Ahumada as its Global CEO. Mr. Ahumada started in the company in October of 2013 as President of Europe, Middle East, and Africa (EMEA), and in this short period successfully led the renewal and expansion of the company’s production sites in Spain (Madrid) and Romania (Bucharest), as well as the definition of the corporate commercial strategy. Both initiatives helped to propel his ascent to the position of the highest executive within the company.
Ciro Ahumada
This is only the second time in history that Mitsubishi Chemical Holding Corporation has chosen a non-Japanese executive as CEO of one of its affiliates. Ciro Ahumada in this way joins a reduced group of occidental top decision-makers that have conquered the summit of the organizational chart of a Japanese company.
In addition to his achievements as the head of the EMEA business, Qualicaps® also took into consideration in Mr. Ahumada’s promotion his broad international experience and knowledge of other cultures. Previous to Qualicaps®, Mr. Ahumada worked as Senior Vice President & Global Head of Sales for Hanwha Q-Cells (Korea; Germany), Managing Director in Grupo Ferrer Internacional (Spain), and Marketing Director of the Nutritional Strategic Business Division of Nestlé, the latter upon his return to Switzerland after working over four years in Chile as an expatriated executive for the company. He also lived and studied in the United States of America, we he earned a Masters in International Business from the University of South Carolina.
Upon assuming his new role on April 2nd, Mr. Ahumada announced his three primary strategic objectives as Global CEO of Qualicaps®. The first of these is to accelerate the company’s growth and international expansion to become a more efficient global partner. The second is to strengthen the company’s competitive advantage to overcome the challenges of an industry that in recent years has been undergoing a radical transformation derived from numerous mergers and acquisitions, as well as the entrance of new competitors and the emergence of niche market segments. Finally, the third strategic objective is to continue to pursue and meet the highest standards of quality and continuous innovation necessary to form part of the pharmaceutical industry.
Other news from the department people
